NAT1 is one of two arylamine N-acetyltransferase (NAT) genes in the human genome, and is orthologous to the mouse and rat Nat2 genes. The enzyme encoded by this gene catalyzes the transfer of an acetyl group from acetyl-CoA to various arylamine and hydrazine substrates. This enzyme helps metabolize drugs and other xenobiotics, and functions in folate catabolism. [From RefSeq]
Yassine et al., 2012 conducted a case-control study comprising of 54 bladder cancer patients and 106 controls to investigate the potential association of NAT1 polymorphism and bladder cancer. The patient group consisted of males over the age of 50 diagnosed with bladder cancer between 2002 and 2008 at St. Georges Hospital and Bahman Hospital in Beirut. NAT1∗14A haplotype showed significantly higher clustering in bladder cancer patients as compared to the controls. On the other hand, significant NAT1∗10 allele clustering was identified in controls than cases. The study identified smoking, prostate-related symptoms, and NAT1∗14A allele to be significantly independent risk factors for bladder cancer in Lebanese males.